Upload
Featured Recent Articles Topics Upload Login Sign Up

Search Results for 'trial pfs'

trial pfs published presentations and documents on DocSlides.

Blinded Sample Size Re-estimation in a Phase III Study Inve
Blinded Sample Size Re-estimation in a Phase III Study Inve
by luanne-stotts
David Morgan (King’s College, London / Consulta...
End-points utilized in
End-points utilized in
by marina-yarberry
End-points utilized in breast cancer clinical ...
End-points utilized in breast cancer
End-points utilized in breast cancer
by evelyn
clinical . trials - Discussion. Novartis Oncology...
Her-2 negative MBC
Her-2 negative MBC
by conchita-marotz
10/25/2016. Objectives. General principles. Endoc...
Blinded Sample Size Re-estimation in a Phase III Study Investigating Progression Free Survival
Blinded Sample Size Re-estimation in a Phase III Study Investigating Progression Free Survival
by naomi
David Morgan (King’s College, London / Consultan...
Molecular Lessons Learnt from Clinical Trials in the Last Decade
Molecular Lessons Learnt from Clinical Trials in the Last Decade
by altigan
Andrew X. Zhu, MD, PhD. Harvard Medical School. Ma...
Exploring the Power of Radioimmunobiology
Exploring the Power of Radioimmunobiology
by jaena
. via switching the . Radionuclides, Ligands and I...
Have the OPTIMOX-2, CAIRO-3, COIN, DREAM and other recent t
Have the OPTIMOX-2, CAIRO-3, COIN, DREAM and other recent t
by sherrill-nordquist
Yes . Deborah . Schrag. , MD, MPH. No. John L. Ma...
Chee Lee,
Chee Lee,
by olivia-moreira
MBBS (Hons), . MMedSci. (. Clin. . Epid. ), . M...
Case Discussion: Second
Case Discussion: Second
by celsa-spraggs
Opinion. 55 year-old woman with . recurrent . ova...
Indolent Non-Hodgkin L
Indolent Non-Hodgkin L
by danika-pritchard
ymphoma. Sobia Ozair. March 8, 2017. MD Anderson ...
PARP and Other DNA Damage Repair Inhibitors in Solid Tumors: An Update
PARP and Other DNA Damage Repair Inhibitors in Solid Tumors: An Update
by ellena-manuel
Program Overview . Discussion Outline. DNA Repair...
ASCO 2012 Review Gynecologic Cancer
ASCO 2012 Review Gynecologic Cancer
by welnews
Nelson Teng, M.D., Ph.D.. Director, Gynecologic On...
End-Points and Rationale for Phase III Trials in HCC: Adjuvant, Intermediate, and Advanced HCC
End-Points and Rationale for Phase III Trials in HCC: Adjuvant, Intermediate, and Advanced HCC
by maniakti
Richard S. Finn, MD. Professor of Clinical Medicin...
by billiontins
2018;36(8):773-9.. Nivolumab Monotherapy (Cohort 1...
Analysis of Sustained MRD-Negativity and Progression-Free Survival of Isa-KRd in High-Risk Newly Diagnosed Multiple Myeloma Additional Data From Planned Interim Analysis of the GMMG-CONCEPT Trial
Analysis of Sustained MRD-Negativity and Progression-Free Survival of Isa-KRd in High-Risk Newly Diagnosed Multiple Myeloma Additional Data From Planned Interim Analysis of the GMMG-CONCEPT Trial
by ayaan
Progression-Free Survival of Isa-. KRd. in High-R...